title: Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.
abstract: Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers associated with response to these therapies. However, the clinical use of such tests is limited by their variable performance and restricted understanding of their biologic significance. Clin Cancer Res; 22(9); 2102-4. ©2016 AACRSee related article by Ock et al., p. 2261.
authors.affiliation: Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut. kurt.schalper@yale.edu.
authors.forename: Kurt A
authors.initials: KA
authors.lastname: Schalper
authors.affiliation: Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut.
authors.forename: Edward
authors.initials: E
authors.lastname: Kaftan
authors.affiliation: Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D061026:Programmed Cell Death 1 Receptor